View more...
Free Webinar: Inflamyloid in Alzheimer's disease: from the amyloid cascade to neuroinflammation

Alzheimer’s disease (AD) was first described in 1906 by the German psychiatrist and pathologist Alois Alzheimer as ‘A peculiar severe disease process of the cerebral cortex’. Since then, tremendous progress has been made in understanding the molecular mechanisms underlying the neuropathology of AD. The cause of sporadic AD still remains poorly understood. However, studies based on familial forms of AD have implicated aberrant cleavage of amyloid precursor protein (APP) to generate toxic species of amyloid beta as a causative agent for disease development. Furthermore, innate immune responses have also been shown to play a role in the pathology of this disease. Current clinical diagnosis of AD is mainly based on mental and physical examinations, and measures to predict and stop disease development remain elusive. Discovery and validation of therapeutic agents that can halt and/or reverse disease pathology is a high priority area of research for AD.

Join our free webinar ‘Inflamyloid in Alzheimer’s disease: from the amyloid cascade to neuroinflammation’ on October 24, 2018, 8:00 AM PST, 4:00 PM BST, 11:00 AM EDT, to learn about:

  • Amyloid plaque generation and amyloid-based clinical trials
  • Involvement of innate immunity in Alzheimer’s disease
  • An overview therapeutic approaches and strategies for AD

Link to the webinar:

About the speakers
Damian Crowther, Ph.D., MRCP
Director of Neuroscience R&D

Dr. Damien Crowther trained in Medicine at the Universities of Cambridge and Oxford, undertaking an intercalated Ph.D. in protein structural biology before M.D./Ph.D. schemes were set up in the UK.  The work on the folding and mis-folding of serine protease inhibitors was his introduction into the proteinopathies that characterize many disorders of old age including Alzheimer, Parkinson and other diseases.  After spending five years in clinical practice, Dr. Crowther returned to academic neuroscience at the turn of the century in the University of Cambridge.  From 2007, he led a group based primarily in the Department of Genetics, working in vitro and in cell and invertebrate models of proteinopathy.  In 2015, he moved into industry, and is now Director of Neuroscience Research & Development at IMED Biotech Unit, AstraZeneca in Cambridge, UK.  The group focuses primarily on neurodegeneration and pain.

View more...
Forgot your password? Reset Password
Request an Account